A Study of the Clinical Benefit of Tobramycin Inhalation Solution

Active, not recruitingOBSERVATIONAL
Enrollment

1,600

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

October 30, 2024

Conditions
BronchiectasisCystic FibrosisLung Infection
Interventions
DRUG

Tobramycin inhalation solution

"Tobramycin Inhalation Solution is a yellowish clear liquid, the main ingredient is tobramycin.~Antimicrobial non-nebulized inhalation preparation according to the current clinical situation, mainly polymyxin, amikacin, depending on the specific circumstances of each hospital."

Trial Locations (1)

Unknown

Rui Yang,MD, Jinan

All Listed Sponsors
lead

Qianfoshan Hospital

OTHER